➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Boehringer Ingelheim
Colorcon
McKesson
Express Scripts

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Trehalose


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Trehalose?

Trehalose is an investigational drug.

There have been 8 clinical trials for Trehalose. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Macular Edema, Acute Coronary Syndrome, and Muscular Dystrophy, Oculopharyngeal. The leading clinical trial sponsors are Bioblast Pharma Ltd., Retina Associates of Florida, P.A., and Stanley Medical Research Institute.

There are two US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for Trehalose
TitleSponsorPhase
Inflammation Reduction by TREhalose AdminisTrationMashhad Razavi HospitalPhase 2
Inflammation Reduction by TREhalose AdminisTrationNational Institute for Medical Research DevelopmentPhase 2
Inflammation Reduction by TREhalose AdminisTrationMashhad University of Medical SciencesPhase 2

See all Trehalose clinical trials

Clinical Trial Summary for Trehalose

Top disease conditions for Trehalose
Top clinical trial sponsors for Trehalose

See all Trehalose clinical trials

US Patents for Trehalose

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trehalose   Start Trial Trabecular meshwork stem cells University of Pittsburgh--of the Commonwealth System of Higher Education (Pittsburgh, PA)   Start Trial
Trehalose   Start Trial Fibrinogen preparations enriched in fibrinogen with an extended alpha chain Mallinckrodt Pharma IP Trading D.A.C. (Dublin, IE)   Start Trial
Trehalose   Start Trial M.tuberculosis vaccines Statens Serum Institut (Copenhagen S, DK)   Start Trial
Trehalose   Start Trial Compositions and methods for inhibition of the JAK pathway Rigel Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trehalose

Drugname Country Document Number Estimated Expiration Related US Patent
Trehalose Australia 2011204557 2030-01-08   Start Trial
Trehalose Canada 2785594 2030-01-08   Start Trial
Trehalose China 102724995 2030-01-08   Start Trial
Trehalose Denmark 2521566 2030-01-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Boehringer Ingelheim
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.